HUE038580T2 - Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra - Google Patents

Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra

Info

Publication number: HUE038580T2
Authority: HU; Hungary
Prior art keywords: diagnosis; treatment; delivery system; drug delivery; neurological disorders
Prior art date: 2012-03-06

Application number

HUE13001491A

Other languages

English (en)

Inventor

Victoria Demina

Heiko Manninga

Armin Goetzke

Alexander Glassmann

Original Assignee

Life Science Inkubator Betr Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-06

Filing date

2013-03-22

Publication date

2018-10-29

2013-03-22 Application filed by Life Science Inkubator Betr Gmbh & Co Kg filed Critical Life Science Inkubator Betr Gmbh & Co Kg

2018-10-29 Publication of HUE038580T2 publication Critical patent/HUE038580T2/hu

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22041—Use of virus, viral particle or viral elements as a vector
- C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22071—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

HUE13001491A 2012-03-06 2013-03-22 Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra HUE038580T2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12001507.8A EP2636746A1 (en)	2012-03-06	2012-03-06	A novel drug delivery system based on JCV-VLP
PCT/EP2013/000656 WO2013131644A1 (en)	2012-03-06	2013-03-06	A novel drug delivery system based on jcv-vlp

Publications (1)

Publication Number	Publication Date
HUE038580T2 true HUE038580T2 (hu)	2018-10-29

Family

ID=48047958

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE13714195A HUE038284T2 (hu)	2012-03-06	2013-03-06	Egy új gyógyszeradagoló rendszer JCV-VLP-T alapján
HUE13001491A HUE038580T2 (hu)	2012-03-06	2013-03-22	Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE13714195A HUE038284T2 (hu)	2012-03-06	2013-03-06	Egy új gyógyszeradagoló rendszer JCV-VLP-T alapján

Country Status (25)

Country	Link
US (3)	US20150045417A1 (hu)
EP (3)	EP2636746A1 (hu)
JP (1)	JP6175080B2 (hu)
KR (1)	KR102058488B1 (hu)
CN (1)	CN104395475B (hu)
AU (1)	AU2013230232B2 (hu)
BR (1)	BR112014021497A2 (hu)
CA (1)	CA2865564C (hu)
CY (1)	CY1120150T1 (hu)
DK (2)	DK2823048T3 (hu)
EA (1)	EA035308B1 (hu)
ES (2)	ES2658941T3 (hu)
HK (1)	HK1208046A1 (hu)
HR (1)	HRP20180221T1 (hu)
HU (2)	HUE038284T2 (hu)
LT (1)	LT2823048T (hu)
MX (1)	MX354004B (hu)
NO (1)	NO2823048T3 (hu)
NZ (1)	NZ629255A (hu)
PL (1)	PL2823048T3 (hu)
PT (2)	PT2823048T (hu)
SG (3)	SG10201607358WA (hu)
SI (1)	SI2823048T1 (hu)
TR (1)	TR201802849T4 (hu)
WO (1)	WO2013131644A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3031820A1 (en)	2014-12-08	2016-06-15	Life Science Inkubator	JC Polyomavirus VLP (virus-like particle) with a targeting peptide
EP3031821A1 (en) *	2014-12-08	2016-06-15	Life Science Inkubator	polyomavirus VLPs with a fusion protein
EP3368694A1 (en) *	2015-10-28	2018-09-05	Life Science Inkubator GmbH	Use of vlp for the detection of nucleic acids
CN106048093A (zh) *	2016-08-02	2016-10-26	北京思尔成生物技术有限公司	Jc病毒的检测方法、试剂盒及其应用
CN111587289B (zh) *	2018-12-18	2024-04-12	纽卫制药有限公司	一种新型药品递送***及其提供方法
EP3670652A1 (en) *	2018-12-18	2020-06-24	NEUWAY Pharma GmbH	Vlp for the treatment of a lysosomal storage disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19543553B4 (de)	1995-11-22	2009-04-09	Deutsches Primatenzentrum Gmbh	VP-Antigene des JC-Virus
DE69821227D1 (de)	1997-04-26	2004-02-26	Rpms Technology Ltd	Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE19916224C1 (de) *	1999-04-10	2000-06-21	November Ag Molekulare Medizin	Synthetisches biologisch aktives Molekül
DE10131145B4 (de)	2001-06-28	2005-07-14	Innovent E.V.	Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
AU2003238008A1 (en) *	2002-06-12	2003-12-31	Temple University Of The Commonwealth System Of Higher Education	Method of cell growth inhibition with agnoprotein
EP2036980A1 (de)	2007-09-14	2009-03-18	Gruber, Jens	Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
EP2093780B1 (en)	2008-02-22	2014-11-05	ABB Technology AG	A spring drive unit, an operating device for an electrical switching apparatus, and method for charging and/or discharging a spring in an operating device for an electrical switching apparatus
EP2394163B1 (en)	2009-02-05	2020-08-19	Biogen MA Inc.	Methods for the detection of jc polyoma virus

2012
- 2012-03-06 EP EP12001507.8A patent/EP2636746A1/en not_active Withdrawn
2013
- 2013-03-06 SG SG10201607358WA patent/SG10201607358WA/en unknown
- 2013-03-06 EA EA201491636A patent/EA035308B1/ru unknown
- 2013-03-06 HU HUE13714195A patent/HUE038284T2/hu unknown
- 2013-03-06 WO PCT/EP2013/000656 patent/WO2013131644A1/en active Application Filing
- 2013-03-06 EP EP13714195.8A patent/EP2823048B1/en active Active
- 2013-03-06 NO NO13714195A patent/NO2823048T3/no unknown
- 2013-03-06 KR KR1020147028123A patent/KR102058488B1/ko active IP Right Grant
- 2013-03-06 MX MX2014010651A patent/MX354004B/es active IP Right Grant
- 2013-03-06 LT LTEP13714195.8T patent/LT2823048T/lt unknown
- 2013-03-06 PL PL13714195T patent/PL2823048T3/pl unknown
- 2013-03-06 NZ NZ629255A patent/NZ629255A/en not_active IP Right Cessation
- 2013-03-06 CA CA2865564A patent/CA2865564C/en active Active
- 2013-03-06 SI SI201330942T patent/SI2823048T1/en unknown
- 2013-03-06 SG SG10202102293QA patent/SG10202102293QA/en unknown
- 2013-03-06 ES ES13714195.8T patent/ES2658941T3/es active Active
- 2013-03-06 PT PT137141958T patent/PT2823048T/pt unknown
- 2013-03-06 EP EP17200325.3A patent/EP3299468A1/en not_active Withdrawn
- 2013-03-06 US US14/383,267 patent/US20150045417A1/en not_active Abandoned
- 2013-03-06 DK DK13714195.8T patent/DK2823048T3/en active
- 2013-03-06 AU AU2013230232A patent/AU2013230232B2/en not_active Ceased
- 2013-03-06 SG SG11201405255SA patent/SG11201405255SA/en unknown
- 2013-03-06 BR BR112014021497A patent/BR112014021497A2/pt not_active IP Right Cessation
- 2013-03-06 JP JP2014560272A patent/JP6175080B2/ja active Active
- 2013-03-06 CN CN201380013112.4A patent/CN104395475B/zh active Active
- 2013-03-22 ES ES13001491.3T patent/ES2661389T3/es active Active
- 2013-03-22 DK DK13001491.3T patent/DK2774991T3/en active
- 2013-03-22 TR TR2018/02849T patent/TR201802849T4/tr unknown
- 2013-03-22 PT PT130014913T patent/PT2774991T/pt unknown
- 2013-03-22 HU HUE13001491A patent/HUE038580T2/hu unknown
2015
- 2015-08-31 HK HK15108461.6A patent/HK1208046A1/xx not_active IP Right Cessation
2018
- 2018-02-05 CY CY20181100133T patent/CY1120150T1/el unknown
- 2018-02-06 HR HRP20180221TT patent/HRP20180221T1/hr unknown
- 2018-06-26 US US16/018,110 patent/US20180296700A1/en not_active Abandoned
2019
- 2019-03-15 US US16/354,739 patent/US11291735B2/en active Active

Also Published As

Publication number	Publication date
LT2823048T (lt)	2018-02-26
SG11201405255SA (en)	2014-09-26
CA2865564A1 (en)	2013-09-12
EP2823048A1 (en)	2015-01-14
EP2636746A1 (en)	2013-09-11
US20190201549A1 (en)	2019-07-04
WO2013131644A1 (en)	2013-09-12
JP2015513550A (ja)	2015-05-14
CN104395475B (zh)	2018-11-16
PL2823048T3 (pl)	2018-05-30
AU2013230232A9 (en)	2018-12-13
BR112014021497A2 (pt)	2019-07-16
HK1208046A1 (en)	2016-02-19
AU2013230232B2 (en)	2019-01-03
DK2774991T3 (en)	2018-03-12
MX2014010651A (es)	2015-05-15
KR20150003186A (ko)	2015-01-08
NO2823048T3 (hu)	2018-04-07
US11291735B2 (en)	2022-04-05
SI2823048T1 (en)	2018-04-30
EP3299468A1 (en)	2018-03-28
SG10201607358WA (en)	2016-10-28
EP2823048B1 (en)	2017-11-08
JP6175080B2 (ja)	2017-08-02
EA035308B1 (ru)	2020-05-27
US20150045417A1 (en)	2015-02-12
ES2658941T3 (es)	2018-03-13
AU2013230232A1 (en)	2014-10-02
NZ629255A (en)	2016-09-30
SG10202102293QA (en)	2021-04-29
WO2013131644A8 (en)	2013-12-12
KR102058488B1 (ko)	2019-12-23
US20180296700A1 (en)	2018-10-18
ES2661389T3 (es)	2018-03-28
CN104395475A (zh)	2015-03-04
PT2823048T (pt)	2018-02-09
TR201802849T4 (tr)	2018-03-21
CA2865564C (en)	2021-06-08
HUE038284T2 (hu)	2018-10-29
HRP20180221T1 (hr)	2018-04-20
MX354004B (es)	2018-02-08
PT2774991T (pt)	2018-03-07
DK2823048T3 (en)	2018-02-12
CY1120150T1 (el)	2018-12-12
EA201491636A1 (ru)	2015-05-29

Publication	Publication Date	Title
GB2492487B (en)	2015-09-16	Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
HK1213503A1 (zh)	2016-07-08	藥物遞送醫療裝置
HK1209456A1 (en)	2016-04-01	Oligonucleotide for the treatment of muscular dystrophy patients
HK1205928A1 (en)	2015-12-31	Ocular drug delivery system
HK1208830A1 (en)	2016-03-18	Drug delivery device for the treatment of patients with respiratory diseases
IL237649B (en)	2018-08-30	Polymer meters drug for use in the prevention, diagnosis and/or treatment of diseases of the joint
PT2838539T (pt)	2017-11-15	Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos.
HUS2000020I1 (hu)	2020-07-28	Ciklezonid a légúti betegségek kezelésére lovaknál
HK1215787A1 (zh)	2016-09-15	用於治療疼痛的藥物組合
HK1207860A1 (en)	2016-02-12	2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
EP2709670A4 (en)	2015-01-21	TARGETED ADMINISTRATION OF PROTEINS ACROSS THE HEMATO-ENCEPHALIC BARRIER
IL222890A0 (en)	2012-12-31	Medicaments for the treatment of il-1beta related conditions
IL235058A0 (en)	2014-12-31	Pharmaceutical combinations for the treatment of metabolic disorders
EP2776042A4 (en)	2015-10-07	DRUG POLYTHERAPY FOR THE TREATMENT OF SOLID TUMORS
EP2819741A4 (en)	2015-07-22	SOLVENT MEDICINAL IMPLANTS FOR THE INTRACOCHLEAR RELEASE OF THERAPEUTICS FOR THE TREATMENT OF EARLIER DISEASES
HUE038580T2 (hu)	2018-10-29	Hatóanyag bejuttató rendszer neurológiai rendellenességek kezelésében, vagy diagnózisában való felhasználásra
EP2750606A4 (en)	2015-04-29	METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
GB201511770D0 (en)	2015-08-19	Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
PL2774991T3 (pl)	2018-05-30	System dostarczania leków do stosowania w leczeniu lub diagnostyce zaburzeń neurologicznych
PL2861568T3 (pl)	2019-11-29	Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca
EP2869796A4 (en)	2016-06-29	PATIENT TREATMENT SYSTEM
ZA201306759B (en)	2014-05-28	Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system
HK1202239A1 (en)	2015-09-25	Combination drug therapy for the treatment of solid tumors